Drug intelligence / Profile preview

P2

Development stage: Preclinical
Modality: Antibody-Based Therapeutics
Administration: Injected

Overview

P2 is a polyclonal anti-amylin antibody generated in rabbits using the N-terminal of amylin peptide as an immunogen. It is being investigated as a passive amylin immunotherapy for Alzheimer's disease (AD). Preclinical studies in APP/PS1 mouse models of AD pathology and HuAmy-APP/PS1 mice indicated that P2 was well-tolerated, did not induce microhemorrhages or other adverse effects, and showed a trend towards enhanced recognition memory and lower blood glucose levels.

Targets

IAPP (Islet Amyloid Polypeptide)CGRP (Calcitonin gene-related peptide)

Beyond the preview

Go deeper on P2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P2.

Explore the full profile